Russian biopharma Biocad was ahead of the curve when it concentrated its initial drug development efforts in then-nascent biosimilars. With a handful of biosimilars assets now launched in Russia and beyond and more in the pipeline, the St. Petersburg-based company increasingly is turning its attention to novel drugs, with an eye to expanding its market in a big way.